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Abstract: Gastric adenocarcinoma occurs via a sequence of molecular events known as the Correa’s Cascade which often 
progresses over many years. Gastritis, typically caused by infection with the bacterium H. pylori, is the first step of the 
cascade that results in gastric cancer; however, not all cases of gastritis progress along this carcinogenic route. Despite re-
cent antibiotic intervention of H. pylori infections, gastric adenocarcinoma remains the second most common cause of 
cancer deaths worldwide. Intestinal metaplasia is the next step along the carcinogenic sequence after gastritis and is con-
sidered to be a precursor lesion for gastric cancer; however, not all patients with intestinal metaplasia develop adenocarci-
noma and little is known about the molecular and genetic events that trigger the progression of intestinal metaplasia into 
adenocarcinoma. This review aims to highlight the progress to date in the genetic events involved in intestinal-type gastric 
adenocarcinoma and its precursor lesion, intestinal metaplasia. The use of technologies such as whole genome microarray 
analysis, immunohistochemical analysis and DNA methylation analysis has allowed an insight into some of the events 
which occur in intestinal metaplasia and may be involved in carcinogenesis. There is still much that is yet to be discovered 
surrounding the development of this lesion and how, in many cases, it develops into a state of malignancy.  
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1. INTRODUCTION 
1.1. Intestinal Metaplasia 
  Intestinal metaplasia (IM) is the term used to describe 
premalignant lesions of the stomach that are often present 
before and during the development of gastric cancer (GC). 
Precancerous or premalignant lesions are defined as lesions 
that precede invasive cancers in which many of the genetic 
abnormalities and phenotypic characteristics of invasive can-
cer are present but not yet fully expressed [1]. In 1955, 
Morson first described the progression of gastric intestinal 
metaplasia into gastric epithelial dysplasia and the subse-
quent development of gastric adenocarcinoma [2, 3]. Gastric 
tissues exposed to mutagens and/or carcinogens resulted in 
development of IM alongside GC; IM development was also 
demonstrated in rats following administration of N-methyl-
N’-nitro-N-nitroguanidine via drinking water [4, 5], and fol-
lowing exposure to radiation [6]. In contrast, it has been pro-
posed that IM may not always be a premalignant condition in 
GC development, but rather that intestinal-type cells in IM 
and GC may occur independently of one another [7]. 
1.2. Gastric Cancer and the Correa’s Cascade of Car-
cinogenesis 
  Gastric adenocarcinoma remains the second leading 
cause of cancer death worldwide, accounting for approxi-
mately 10% of all newly diagnosed cancers [3]. It is the most  
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common form of malignant gastric tumor, accounting for 
about 90% of stomach cancers. Lack of early diagnosis is 
responsible for the high mortality rates as the disease is usu-
ally incurable when diagnosed at an advanced stage with a 5-
year survival rate ranging from 5-15% [8]. Clinical outcome 
is therefore optimized by early stage diagnosis [1]. There is a 
recognized need to be able to identify and eliminate precur-
sor lesions in order to treat many cancers, and a significant 
reduction in the mortality rate of GC could be achieved by 
the implementation of early diagnostic methods. There are 
two main types of gastric adenocarcinoma according to the 
Lauren classification defined as intestinal-type and diffuse-
type. These histopathological variants have been shown to 
differ greatly in the phenotypic characteristics at the precur-
sor stage [9]. Intestinal-type carcinomas display obvious 
glandular differentiation and arise from gastric cells that 
have undergone IM through a series of histological changes 
known as the Correa’s Cascade of Gastric Carcinogenesis. 
Diffuse-type carcinomas are typically poorly differentiated 
and may arise from either native gastric cells or those that 
have undergone IM [10], there are no known defined precur-
sor lesions for this type of cancer [11, 12]. The Lauren clas-
sification is widely used as it describes two biological enti-
ties that are different in epidemiology, etiology, pathogenesis 
and behaviour. The Correa’s Cascade of Gastric Carcino-
genesis is a model that refers only to intestinal-type carci-
noma. The cascade outlines a process of carcinogenesis 
which is a gradual transition from initial gastritis to diffuse, 
chronic gastritis, mucosal atrophy, intestinal metaplasia, 
dysplasia, and finally, carcinoma [1, 13, 14]. The initiation 
of gastritis in the stomach is often caused by infection with 
Helicobacter pylori, a bacterial pathogen that frequently 380    Current Genomics, 2007, Vol. 8, No. 6  Holmes et al. 
colonizes the intestinal mucosa of humans and animals. The 
organism may be carried asymptomatically for many years; 
however, it is also a recognized cause of chronic gastritis, 
gastric ulcers and gastric adenocarcinoma. The evidence 
linking this pathogen to GC led to H. pylori becoming classi-
fied as a class 1 carcinogen by the World Health Organiza-
tion [15]. Fig. (1) shows a diagrammatic representation of 
the carcinogenic cascade, this diagram is a modification of 
the “hypothesis of gastric cancer etiology” as proposed by 
Correa [16]. Fig. (2) shows the pathology of the key steps 
along the Correa’s cascade of carcinogenesis. H&E stained 
paraffin-embedded tissue sections are presented, starting 
with normal gastric mucosa, Fig. (2a), followed by initial H. 
pylori-associated gastritis in Fig. (2b) and progression into 
IM in Fig. (2c), and finally intestinal-type GC in Fig. (2d).  
  Human stomach carcinogenesis is a multistep process 
involving genetic instability and numerous genetic and epi-
genetic changes in oncogenes, tumor-suppressor genes, cell-
cycle regulators, cell adhesion molecules and DNA repair 
genes. The two different histological types of cancer: gastric 
and diffuse, arise from different combinations of these 
changes and steps; Tahara et al. [17] were amongst the first 
to determine the pathway of genetic events for the two types 
of cancer [12]. Gastric adenocarcinoma may further be cate-
gorised as “mixed” type consisting histologically of a com-
bination of intestinal and diffuse type. The variation of com-
plex phenotypes both during and preceding the development 
of GC has led to substantial research interest in gene expres-
sion. There have been many recent studies on the regulation 
of genes and their expression in many types of cancer, in-
cluding GC; however, there are limited studies to date on the 
expression and regulation of genes during the precursor 
stages of GC. Recent research progress on gene expression 
and regulation in GC will be discussed in section 5.  
2. MOLECULAR MARKERS OF IM TYPE AND CAR-
CINOGENIC PROGRESSION 
2.1. IM Classification 
  Further to the Lauren classification of types of gas-
troadenocarcinoma which are described as intestinal-type 
and diffuse-type, IM has more complex classifications which 
begin initially with two types: small-intestine-type and colo-
nic-type. IM develops when gastric stem cells are diverted 
from the production of normal gastric cells (eg. surface cells, 
chief cells, parietal cells) towards the production of cells 
typical of the small or large intestine (eg. absorptive cells, 
goblet cells, paneth cells) [18]. Classification of IM into 
complete and incomplete types depending on the presence of 
paneth cells was first proposed by Kawachi and colleagues 
[19], and a further classification based on mucin secretion 
patterns and morphology defined small intestine-type and 
colonic-type. Three classes of IM were described by Jass and 
Filipe [20] based on morphology and classical mucin-
staining using periodic acid-Schiff, Alcian blue and high iron 
diamine staining methods: Type I, Type II and Type III. 
Type I is described morphologically as complete IM contain-
ing all intestinal cell types including absorptive cells, with 
predominantly sialomucin- and some sulphomucin-secreting 
goblet cells. Type II is described as incomplete IM that lacks 
recognizable absorptive cells, and has only sialomucin-
secreting goblet cells. Types I and II are also described as 
small-intestine-type. Type III is described as incomplete with 
only sulphomucin-secreting goblet cells and is also the colo-
nic-type rather than small-intestine type. Type III IM confers 
a 4-fold greater risk of developing GC than Type I [18, 20].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The Correa’s Cascade of Carcinogenesis [16]. 
  These IM classifications are generally accepted yet they 
are only based on intestinal, and not gastric, properties of the 
cells [19, 21]. This has led to more recent improved classifi-
cations of IM consisting of gastric or G-type, intestinal or I-
type and mixed gastric-intestinal or GI-type, based on the 
cellular origin of the cancer cell [19, 21]. Recent studies used 
immunohistochemical analyses to define the precursor lesion 
type; the type of IM can have significant implications in pre-
dicting progression of disease, for example, Type III IM con-
fers a 4-fold greater risk of GC than does Type I IM. 
  Immunohistochemical analysis of the two phenotypically 
distinct types of cancer precursor lesions has led to the iden-
tification of a number of histological “markers” that can be 
used to determine whether GC, and indeed IM itself at the Genetic Mechanisms and Aberrant Gene Expression  Current Genomics, 2007, Vol. 8, No. 6    381 
early stages, is of the gastric or intestinal type [3, 7, 21, 23, 
24]. Progress with this has accelerated with microarray tech-
nology to determine a small profile of gene expression 
changes that correlates with progression of IM into gastric 
adenocarcinoma [8].  
2.2. Genetic Markers of IM 
  Gene markers that have been identified as indicators of 
the progression and type of IM are cdx1 and cdx2, sox2, muc 
2, muc5AC, muc6, claudin-4, mkk4, stratifin, villin-1, and 
hif-1 [3, 11, 19, 21, 23-31]. The caudal related homologue 
genes (cdx1 and cdx2) are evolutionarily conserved both in 
molecular structure and function and have critical function 
during the development of both foetal and adult intestinal 
epithelia. When expressed, they modulate proliferation, 
apoptosis, cell-adhesion, and columnar morphology. They 
are also necessary for expression of intestine-specific genes 
and promotion of the mature intestinal phenotype. Although 
several studies suggest that cdx homologues may act as tu-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathology of Intestinal Metaplasia:  
There are two types of metaplastic change that occur in the setting of chronic gastritis, pyloric metaplasia and intestinal metaplasia, often occurring in combi-
nation.  
Intestinal metaplasia is the process whereby antral, body and fundic mucosa is partially replaced by metaplastic columnar absorptive cells, goblet cells and 
Paneth cells of intestinal morphology (2c). Intestinal metaplasia can be further subdivided into complete (Type I) and incomplete (Type II) types. In complete 
IM, the gastric mucosa changes to a pattern identical to that of small intestinal epithelium with villous-like projections and the development of a brush border 
on the surface epithelium. In incomplete IM, absorptive cells are absent, whereas columnar cells with the appearance of gastric foveolar cells and goblet cells 
are retained. In practice IM is not subdivided and the presence of goblet cells is used as the criteria for the diagnosis. IM can be graded into focal (less than 1/3 
of mucosa involved) and extensive (>1/3 involved) or into a three tiered system, as recommended by the Sydney system, of mild (<1/3), moderate (1/3 to 2/3 
involved) or severe (>2/3 involved) [22]. 
Fig. (2). H&E Stained Histopathology Sections of a) Normal Gastric Mucosa, b) Gastritis, c) Intestinal Metaplasia and d) Intestinal-Type 
Gastric Cancer. 
(2c) Intestinal Metaplasia (H&E x40 magnification): antral-type 
gastric mucosa with gastric glands containing numerous intesti-
nal-type goblet cells. 
(2d) Gastric Adenocarcinoma (H&E x40 magnification): 
gastric mucosa infiltrated by a moderately differentiated 
adenocarcinoma intestinal-type. 
(2a) Normal (H&E magnification x40): normal specialized 
gastric mucosa 
(2b) Chronic Gastritis (H&E magnification x40): antral-type 
mucosa with a moderate chronic gastritis (H. pylori-associated) 382    Current Genomics, 2007, Vol. 8, No. 6  Holmes et al. 
mor suppressors in the colon, ectopic expression of cdx1 and 
cdx2 in the gastric mucosa is involved in the development of 
precancerous IM [30]. 
 Silberg  et al. [25] first demonstrated that ectopic expres-
sion of cdx2 directed to the gastric mucosa of transgenic 
mice induced gastric IM. Cdx2 expression in gastric mucosa 
was achieved through the derivation of transgenic mice in 
which the mouse cdx2 cDNA was under the control of cis-
regulatory elements of the transcription factor foxA3 in a 
yeast artificial chromosome (YAC). Histological examina-
tion of the gastric mucosa of the foxA3/cdx2 mice revealed 
the presence of alcian blue-positive intestinal-type goblet 
cells along with the RNA expression of the intestine-specific 
genes villin, fabpi, tff3, gcc and muc2, as detected by North-
ern blot analysis. Tff3 and muc2 are normally expressed in 
goblet cells in the small intestine and colon; fabpi is nor-
mally expressed in both absorptive enterocytes and goblet 
cells; villin is expressed in microvilli, which are present pre-
dominantly on the apical surface of goblet cells and absorp-
tive enterocytes. The mice developed an IM phenotype with 
predominantly sulphated mucins; this is consistent with a 
Type III human gastric IM, where sulphated mucins are the 
predominant type [25]. The histological and molecular 
changes induced by cdx2 expression in mice mimic the 
changes that take place during the development of human 
IM, that is, the appearance of goblet cells and the activation 
of intestinal genes in the gastric epithelium. This study dem-
onstrated the first causal link between cdx2 expression and 
IM [25].  
  Many subsequent studies have demonstrated the role of 
the cdx1 and cdx2 transcription factors in the initiation of 
IM. Their role as transcriptional activators of other intestine-
specific genes has also been widely reported. Almeida et al. 
[23] performed immunohistochemistry staining of tissues 
from a cohort of patients with IM, gastric adenocarcinoma 
and a range of asymptomatic and dyspeptic patients. Staining 
was used to detect Cdx1, Cdx2, Muc2 and Muc5AC and it 
was revealed that Cdx1 and Cdx2 were consistently ex-
pressed in IM and in a subset of gastric carcinomas. They 
reported that Cdx1 and Cdx2 expression was independent of 
the type of IM and of gastric carcinoma, and that it was sig-
nificantly associated with expression of the intestinal mucin 
Muc2 [23]. Further to this, Mesquita et al. [27] evaluated the 
role of cdx-1 and cdx-2 in muc2 transcription using co-
transfection experiments with expression vectors encoding 
Cdx-1 and Cdx-2. Following successful transactivation of 
the muc2 promoter with expression vectors, gel-shift assays 
were used to identify two Cdx2 binding sites at –177/-171 
and –191/-187. Mutation of these two binding sites subse-
quently abolished transactivation by Cdx-2, thus demonstrat-
ing a functional role for Cdx2 in regulating Muc2 mucin 
gene promoter activity [27]. A further study demonstrates 
that the cdx2 transcription factor regulates furin expression 
during intestinal epithelial cell differentiation; furin activity 
is essential for morphological differentiation of intestinal 
epithelial cells [31]. 
2.3. Improved IM Classification and Identification of 
Further Gene Markers 
  To further clarify the molecular mechanisms underlying 
the development of IM, a new classification was proposed to 
first provide a better explanation of the phenotypic status 
[19, 21, 24]. This takes into account both the gastric and in-
testinal properties of IM, thus dividing IM type into two ma-
jor groups; a gastric/intestinal (GI)-mixed type, and a solely-
intestinal (I) type. The morphological and biochemical dif-
ferentiation status toward “gastric” and/or “intestinal” pro-
vide fundamental information for this classification system 
making gastrointestinal markers important to judge the pro-
gression. The first morphological change is the appearance 
of intestinal goblet cells and changes occur in mucin-type 
molecules. The muc5AC and muc6 genes of the gastrointes-
tinal tract are mainly expressed in gastric foveolar mucosa 
and pyloric glands, respectively. The muc2 gene encodes a 
typical secretory gel-forming mucin, which represents the 
predominant form in human intestinal tissues. These genes 
and their consequent morphological changes are useful 
markers to distinguish between a gastric and intestinal phe-
notype. Sox2 is proposed as a potential marker for the gastric 
phenotype as transcript and protein expression was demon-
strated in human stomach both with and without IM [21, 24]. 
A transcriptional expression profile was characterized for 
normal gastrointestinal tract isolated stomach glands from 
patients with a range of IM types including G, GI-mixed and 
I types. RT-PCR was used to detect expression levels of 
muc5AC, muc6, muc2, villin-1, cdx1, cdx2 and sox2. In 
normal gastrointestinal tract, the expression of muc5AC and 
muc6 was higher in the stomach than in intestine and con-
versely, muc2 and villin-1 expression levels were greater in 
the intestine than in the stomach. In G type glands, muc5AC 
and muc6 showed the greatest levels of expression and those 
of muc2 and villin-1 were significantly lower. Expression of 
muc5AC and muc6 gradually decreased during the intestinal 
shift from G to GI, and from GI-mixed to I type during IM 
progression. Simultaneously, muc2 was upregulated during 
the entire intestinal cell shift, but villin-1 was only upregu-
lated from G to I, and not from GI to I type. Sox2 expression 
also gradually decreased as cdx 1 and 2 expression increased 
during the transition of IM from G to GI and to the I type. 
This study defines a set of gastrointestinal differentiation 
marker genes that can be used to assess the type and direc-
tion of progress of IM in immunohistochemical and molecu-
lar biological studies [21, 24].  
  The mucins are well recognized as important marker 
molecules for the classification and progression of IM of the 
stomach [32, 33], as well as having defined expression pat-
terns according to the presence or absence of Helicobacter 
pylori infection [34, 35]. Mucin immunohistochemistry 
might feasibly replace classic histochemistry for the classifi-
cation of IM into complete and incomplete types [32]. Many 
studies correlate the definitions of these IM types according 
to mucin expression: in type II/III or incomplete IM the 
mucins usually expressed in the stomach (muc1, muc5AC 
and muc6) are present; in type I or complete IM, muc2 is 
aberrantly expressed and there is decreased or absent expres-
sion of muc1, muc5AC and muc6 [21, 24, 32-34, 36]. The 
presence or absence of H. pylori infection has also been 
shown to correlate with mucin expression and onset of IM; 
IM usually leads to clearing of H. pylori. Where IM and H. 
pylori are found together, a particular pattern of incomplete 
IM is apparent, with expression of muc1 and muc5AC and 
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H. pylori is absent, high levels of muc2 expression has been 
demonstrated regardless of the IM type [34]. A study on the 
different mucins expressed in different types and stages of 
adenocarcinoma suggested that the cellular mucin pheno-
types result from distinct genetic alterations. Tumors were 
subclassified into 4 groups: gastric-phenotype, intestinal-
phenotype, mixed-phenotype and unclassified-phenotype. 
Immunohistochemistry was used to detect chromosomal alle-
lic losses of cancer-related loci, microsatellite instability 
(MSI), and overexpression of the p53 protein. The frequency 
of 3p allelic loss was higher than other markers in gastric-
phenotype cancer, whereas in intestinal-phenotype cancers, 
5q allelic loss was more frequent. Mixed phenotype cancers 
have two distinct genetic types: either LOH or MSI types; 
MSI was only observed in mixed phenotype cancers. Over-
expression of p53 gene is common in intestinal-type cancers, 
this is thought to play a fundamental role in the carcinogene-
sis of early adenocarcinomas of the stomach [33].  
 Cunningham  et al. [3] investigated whether any genes 
up-regulated in gastric adenocarcinoma were also expressed 
in precursor lesions. Three target genes were studied; 
claudin-4, mitogen-activated protein kinase kinase 4 (mkk4) 
and 14-3-3 (stratifin). Claudin-4 (cldn4) is a member of the 
claudin gene family that includes the genes claudin-1 (cldn1) 
and claudin-7 (cldn7) which have been shown to be up-
regulated in a variety of tumors and their associated prema-
lignant lesions, including colorectal cancer and cancers of 
the pancreas and oesophagus [3, 36]. Expression of cldn7 in 
a tff1 knockout (-/-) mouse model is weak during IM, but 
becomes strongly expressed and over-expressed in dysplasia 
and intestinal-type adenocarcinoma, respectively. No over-
expression was detected in diffuse-type carcinoma suggest-
ing that cldn7 would be useful marker for early intestinal-
type GC [36]. Mkk4 is thought to be a tumor-suppressor 
gene; it is mutated in approximately 4% of many tumor types 
including pancreas, biliary, breast and colon. Stratifin is in-
volved in diverse cellular processes including cell cycle pro-
gression, apoptosis, signal transduction and stress response. 
There are conflicting reports on its role in cancers as it has 
been reported to be up-regulated in pancreas and lung can-
cer; yet down-regulated in breast, prostate and liver cancer. 
The expression pattern of these proteins in normal gastric 
mucosa, premalignant intestinal metaplasia and gastric 
epithelial dysplasia, invasive gastric adenocarcinoma, and 
gastric adenocarcinoma metastases was studied. Immunohis-
tochemistry assays were performed using tissue microarrays; 
all three proteins were positive markers of IM and adenocar-
cinoma. The reported findings present a panel of three mark-
ers which may provide nearly 100% sensitivity and specific-
ity in identifying the gastric adenocarcinoma precursor le-
sions intestinal metaplasia and gastric epithelial dysplasia. 
Potential future application of this is suggested endoscopi-
cally, whereby labelled antibodies could be used to detect 
precursor lesions during the endoscopic procedure as a 
screening method for patients at increased risk for adenocar-
cinoma [3]. 
2.4. Progression of IM into Gastric Adenocarcinoma 
  Studies using cdx-2 transgenic mice have defined a key 
role of IM directly leading to malignant and invasive gastric 
adenocarcinoma [28]. Many epidemiological studies have 
found an association between the formation of IM and the 
development of GC, yet there was little direct evidence that 
IM is, in fact, a precursor lesion for gastric carcinoma. How-
ever, it was demonstrated that the gastric fundic mucosa of 
cdx-2 transgenic mice was completely changed into intesti-
nal metaplastic mucosa [25, 28]. Further pathological ex-
amination of the intestinal metaplastic mucosa of the cdx-2 
transgenic mice revealed formation of gastric polyps in 
100% of the mice after 80 weeks versus no polyps in non-
transgenic mice of the same age. Immunohistochemical 
staining was used to determine the type of gastric adenocar-
cinoma and clarify the activation of a molecular signalling 
pathway during carcinogenesis known as the Wnt signalling 
pathway. Indicators for activation of this pathway were de-
tected by staining for nuclear translocation of -catenin in 
the polyp epithelium and the presence of mutations in the 
apc and p53 genes. The transgenic mice that carried apc mu-
tation or p53 deficiency developed gastric polyps at a much 
earlier age thus indicating the importance of mutations in 
these genes during gastric carcinogenesis. The authors con-
cluded that IM is a precancerous lesion leading directly to 
GC in this model [28]. Cdx-2 expression in stomach cancer 
may be a marker of the progression of gastric carcinogenesis, 
and its activation may represent an early event [1]. Previous 
studies by Tsukamoto et al. [21, 24] also identified the ec-
topic expression of the cdx genes and the down-regulation of 
sox2 as important steps in gastric carcinogenesis progressing 
from IM which could represent important diagnostic and/or 
therapeutic targets.  
  It was demonstrated that the origin of GC cells in cdx2 
transgenic mice is not parietal cells, but intestinal metaplas-
tic epithelial cells that are entirely changed from gastric 
epithelial cells by cdx2 [28]. Although cdx1 induces gastric 
intestinal metaplasia, this differs from cdx-2 induced IM in 
differentiation, structure and proliferation resulting in the 
discovery of significantly thicker metaplastic mucosa in 
cdx1 transgenic mice than that in cdx2 transgenic mice [29]. 
It is widely believed that the phenotypic expression of tumor 
cells is the same as that of the tissue of origin of the cells 
[19]. However, this conflicts with Lauren’s histological clas-
sification of cancers as the gastric or “G” type of recent clas-
sifications correlates with the “intestinal” type of Lauren, 
and the “I” type in more recent classification correlates with 
the “diffuse” type of Lauren. The improved IM classification 
system is needed to allow for studies of the histogenesis of 
GC and phenotypic expression at the cellular level [19].  
  Expression levels of li-cadherin (cdh17) were reported to 
be significantly higher in chronic atrophic gastritis with IM 
than in GC, and lower in poorly differentiated tumors than in 
well- and moderately differentiated tumors, as well as show-
ing increased expression levels in lymph node metastasis. No 
li-cadherin is expressed in normal tissues and expression 
levels were correlated with the GC differentiation grade. 
This suggests that overexpression of li-cadherin is an early 
event in gastric carcinogenesis and expression levels are as-
sociated with invasiveness and lymph node metastasis. Li-
cadherin thus represents a useful biomarker for GC, as an 
early detection marker and also a discriminator of invasive-
ness, lymph node metastasis and potentially, patient progno-
sis [37].  384    Current Genomics, 2007, Vol. 8, No. 6  Holmes et al. 
3. GENE REGULATION DURING THE PROGRES-
SION OF IM AND GASTRIC CARCINOGENESIS 
  Studies of transcriptional regulatory control and transac-
tivation involving sox2, cdx1 and cdx2 have shown that the 
expression patterns of sox2 and cdx1/2 appear inversely re-
lated and the down-regulation of sox2 may be an important 
mechanism in IM development. It is suggested that either 
sox2 may negatively regulate cdx1/2 expression or vice 
versa [21, 24].  
    More recent studies demonstrate that Cdx2 drives the 
transcription of furin during intestinal epithelial cell differen-
tiation [31] and that the gene oct-1 is over-expressed in intes-
tinal metaplasia, and binds to, but does not transactivate, 
cdx2 in gastric cells [38]. Furin is a calcium-dependent ser-
ine protease that processes many proteins including trans-
forming growth factor-1 (Tgf-1), Bmp-4 and the cell ad-
hesion protein E-cadherin. The fur gene, which encodes 
furin, is driven by three promoters P1, P1A and P1B and the 
cdx2 gene has been shown to induce the P1 promoter 
through a specific cdx2-DNA binding element. Furin expres-
sion is significantly enhanced during differentiation of intes-
tinal epithelial cells and it is suggested that the inhibition of 
E-cadherin maturation by furin may affect intestinal epithe-
lial cell differentiation [31]. Oct-1 is a ubiquitously ex-
pressed transcription factor that has been implicated in the 
activation of the mouse cdx2 promoter in pancreatic and 
intestinal cell lines. A significant association was observed 
between oct-1 and cdx2 expression in the gastric carcinoma 
cell lines, GP220 and MKN45; however, whilst oct-1 was 
shown to bind to the cdx2 promoter, a direct effect of oct-1 
in the transactivation of cdx2 was not demonstrated [38]. 
4. GENETIC RISK FACTORS ASSOCIATED WITH 
IM/GC 
 Helicobacter  pylori infection is a major risk factor for 
GC and induces many gene expression alterations by initiat-
ing an inflammatory response, so as a direct result many 
cytokines and other pro-inflammatory genes are upregulated. 
A number of polymorphisms have been identified in the pro-
inflammatory cytokine genes which are related to an in-
creased risk of developing GC. The main genes which have 
polymorphisms associated with greater risk of GC are the il-
1 gene cluster, tnf- and il-10 [39-43]. Many cytokine gene 
polymorphisms influence mucosal cytokine expression, gas-
tric inflammation and the long term development of precan-
cerous lesions in H. pylori infection. They have all been de-
scribed and reviewed comprehensively and will not be dis-
cussed in further detail in the present review [39-45]. A Chi-
nese study has reported that a polymorphism in cyp2e1/dra1 
interacts with smoking to increase the risk of advanced pre-
cursor lesions on the pathway to GC [46]. 
5. MOLECULAR EVENTS AND ABERRANT GENE 
EXPRESSION IN GASTRIC CARCINOGENESIS 
  Studies of many types of cancer including GC have so far 
shown that many genetic and epigenetic changes take place 
during tumor progression [10, 47, 48]. As previously dis-
cussed, some initial genetic changes in intestinal-type GC 
can be detected in pre-malignant IM and dysplasia that are 
often involved in the transition of cells from a gastric to an 
intestinal phenotype, such as the cdx and muc genes. Many 
genes have previously been identified as deregulated in some 
way in GC resulting from a multitude of causes; this differs 
in the two types of GC, diffuse- and intestinal-type. Altera-
tions occur at the level of the genome, at the level of signal-
ling, and at the level of transcription and translation. The 
pathways of molecular events in the two types of GC have 
been reviewed comprehensively [10, 12, 17, 47], and Fig. (3) 
shows an overview of the main genetic changes in intestinal-
type GC [12]. This review will focus on changes specifically 
important in intestinal-type GC and its precursor lesions and 
discuss genomic expression profiling studies which have 
highlighted important results for this type of cancer.  
  There are two general, classical groups of gene types 
involved in gastric carcinogenesis, the first are oncogenes. 
This group includes a wide range of genes that are overex-
pressed and commonly have a role in growth, differentiation 
and proliferation. Some of these genes are present at an early 
stage during carcinogenesis, and many are more prominent 
during tumor progression and are involved in metastasis and 
angiogenesis. The second group are known as the tumor-
suppressor genes (TSGs), these genes are all silenced or de-
activated by a variety of mechanisms and often have roles in 
cell cycle regulation and cell death (apoptosis). Tables 1 and 
2 provide shortlists of the main oncogenes (Table 1) and 
TSGs (Table 2) as well as other genes that have aberrant 
expression and/or mutations involved in the progression of 
IM and intestinal-type GC that are discussed in this review. 
All the oncogenes and TSGs in the two types of GC have 
been reviewed comprehensively as stated above, the follow-
ing section aims to highlight some of the more important 
changes in both types of GC incorporating many important 
aberrantly expressed genes that are detected at the precursor 
stages of intestinal-type GC. Recent expansion of the two 
classical groups of oncogenes and TSGs has yielded a third 
category of genes; the microRNA (miRNA) family of regu-
latory molecules [49]. More than 50% of miRNA genes are 
located in cancer-associated genomic regions known as frag-
ile sites; evidence suggests that miRNAs function in concert 
with classical tumor suppressors and oncoproteins to regu-
late key pathways involved in cellular growth. When such 
pathways become deregulated, miRNAs and their targets 
play a key role in tumorigenesis [49, 50]. 
5.1. Oncogenes 
  Gene over-expression has been observed in many GC 
oncogenes including k-ras, c-erbB2, c-met and k-sam [12, 
47]. Of these, c-met and k-sam are more commonly ampli-
fied in diffuse-type GC, whereas c-erbB2 over-expression 
and k-ras mutation are seen in intestinal-type GC but not 
diffuse-type. K-ras has also been reported in the precursor 
lesions IM and adenoma [12, 17, 51], yet has been shown to 
decrease after H. pylori eradication suggesting that H. pylori 
clearance therapy before the formation of stable k-ras muta-
tions will decrease the risk of GC [52]. Further well-
characterized oncogenes include c-myc at 8q24, ErBB2 at 
17q12 and cyclin D at 11q13 [53, 54]. The c-myc gene is a 
regulator of cell cycle and plays a major role in control of 
cell growth, differentiation, apoptosis and neoplastic altera-
tion, its overexpression is a common alteration in many can-
cers and has been reported in gastric neoplasias [55]. Distinct Genetic Mechanisms and Aberrant Gene Expression  Current Genomics, 2007, Vol. 8, No. 6    385 
patterns of c-myc alterations have been shown between in-
testinal and diffuse-type cancers and c-myc locus amplifica-
tion has been implicated as a predictor of aggressiveness in 
intestinal-type GC [55, 56]. Recent studies have demon-
strated an oncogenic role of c-myc involved in regulation of 
the miR-17 microRNA cluster, which is further discussed in 
section 5.3 [49, 50, 57-62]. Cyclins condition the course of a 
cell cycle through the activation of appropriate serine-
threonine kinases, cyclin D1 and E are found to be overex-
pressed in GC [63, 64]. Cyclin D1 is a key cell cycle regula-
tor that may be useful in the diagnosis of early gastric carci-
noma [65, 66]. Cyclin E overexpression has been associated 
with a high incidence of lymph node metastasis, and its ex-
pression was inversely correlated with a 5-year survival rate, 
suggesting that this gene is a useful prognostic indicator, but 
similar results were not obtained for cyclin D1 [63, 64]. Cy-
clin E overexpression also correlated with reduced expres-
sion of the TSGs p53 and p21 [63], but no correlation was 
found with expression levels of the TSG p27 in contrast to 
previous studies [12]. 
  A systematic analysis of the 17q amplicon revealed the 
overexpression of 8 genes in GC [53]. The 17q amplicon 
contains the brca1 locus involved in breast cancer at chromo-
some 17q21; this chromosome also contains a potential TSG 
in GC [67]. Of note amongst the 8 overexpressed genes were 
estAA552509, top2A (both in 82% of tumors) and erb-B2 
(30% of tumors). The role of top2A and erb-B2 in breast 
cancer is well-known; top2A is an enzyme that catalyzes 
functions in DNA replication and is a molecular target for 
many anti-cancer drugs (topo2 inhibitors); erb-B2 is ampli-
fied frequently in breast cancer and is an independent prog-
nostic target. Co-amplification of top2A and erb-B2 is often 
reported in breast cancers, yet in gastric adenocarcinoma, 
overexpression of top2A was independent and more frequent 
than of erb-B2 [53]. A cluster of 5 tightly regulated genes 
were all present at chromosome 19q12, including ccne1. 
Other genes within the 19q12 amplicon were overexpressed 
including genes involved in cell cycle progression and cell 
proliferation, for example; cdc2, centromere protein A 
(cenpA), translin (tsn), tubulin beta 2 (tubb2) and bub1. 
Overall, high expression of the 19q12 gene cluster was sta-
tistically correlated with the cell proliferation gene signature, 
demonstrating an oncogenic role of this amplicon in GC 
[54]. 
  The Egf family of growth factors and cytokines (includes 
Egf, Tgf, IgfII and bFgf) are commonly over-expressed in 
intestinal-type GC. GC cells express neutrophilin-1 (nrp-1), 
a co-receptor for vascular endothelial growth factor (Vegf) 
receptor 2 endothelial cells; Egf induces both nrp-1 and Vegf 
[12]. Vegf has a prominent role in tumor angiogenesis, 
growth and metastasis [68, 69], and its expression correlates 
with disease recurrence in patients with early gastric carci-
noma [70]. The vegf gene encodes a multifunctional cyto-
kine that is crucial in angiogenesis during the development 
of cancer and activates p38 Kinase, which in turn, mediates 
actin reorganization and cell migration in human endothelial 
cells. p38 may thus also be an important regulator of angio-
genesis [70]. Vegf-C is a member of the Vegf family that can 
induce lymphangiogenesis, a critical factor in the progres-
sion of many malignant tumors. Vegf-C and lymphatic ves-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Schematic representation of the main genetic and epigenetic changes involved in the development of intestinal-type gastric cancer, 
reproduced with some modifications from Smith et al. 2006 [12].  386    Current Genomics, 2007, Vol. 8, No. 6  Holmes et al. 
sel density (LVD) are related to lymph node metastasis 
(LNM) and poor prognosis of patients in GC, and serum 
vascular endothelial growth factor-C (SVegf-C) has been 
recently proposed as a useful biomarker for LNM and prog-
nosis in GC [69]. Fgf7 is a mesenchyme-derived growth fac-
tor that is expressed in normal adult stomach, it acts specifi-
cally on cells of epithelial origin, stimulating their migration, 
differentiation and proliferation. Expression levels are mark-
edly elevated in gastric inflammation and cancer [71].  
  The matrix metalloproteinases (Mmps) are key players in 
the promotion of cancer progression by increasing cancer-
cell growth, migration, invasion, metastasis and angiogenesis 
[72, 73]. They function in the cell as primary matrix degrad-
ing proteases, collectively able to degrade all protein compo-
nents of the extracellular matrix [73]. Microarray studies 
have revealed the increased expression of mmp1, mmp2, 
mmp3, mmp7, mmp9, mmp10, mmp11, mmp12, mmp13 
and mmp14 in GC [8, 70, 74-76].  
  Cell-adhesion and metastasis-related genes are another 
subset of genes involved in carcinogenesis. E-cadherin is a 
commonly mutated cell adhesion gene, but is more often 
linked with diffuse-type cancer than intestinal-type. E-
cadherin binds -catenin in normal cell functioning; how-
ever, deregulation of the -catenin pathway is associated 
with the loss of this binding, resulting in nuclear accumula-
tion of -catenin [77, 78]. The H. pylori cagA gene has been 
shown to be one of the mechanisms of this deregulation, by 
interacting with E-cadherin itself and causing consequent de-
regulation of the -catenin pathway [78].  
  Other genes involved in gastric carcinogenesis, disease 
progression and survival are hypoxia-inducible factor-1 
(Hif-1) [11], the novel gene urg4 [79], r-ras [80] fhl2 [81], 
and the ribosomal protein L15, which has been associated 
with cell proliferation in GC, outlining its potential as a the-
rapeutic target [82]. All GC cell lines and tissues exhibit 
abnormal cd44 transcripts containing the intron 9 sequence, 
a feature that has also been observed in 60% of gastric IM 
but is absent from normal mucosa [12]. 
5.2. Tumor Suppressor Genes (TSGs) 
  Cellular growth and proliferation are tightly regulated in 
cells; loss of regulation is a crucial early step in tumorigene-
sis. TSGs are often involved in apoptotic pathways which 
prevent cells being driven into an overactive proliferative 
state. Two pathways that are important in apoptosis are Wnt 
signal transduction and the -catenin pathway. The Wnt sig-
nal transduction pathway plays an important role in gastric 
carcinogenesis and its activation has been reported in one-
third of gastric adenocarcinomas. The activation of the Wnt 
pathway is frequently caused by -catenin mutation which 
occurs in both intestinal- and diffuse- type GC [83]. In the 
cytoplasm, in the absence of Wnt, -catenin is rapidly phos-
phorylated and degraded by Apc; however the stabilization 
of -catenin in the cytoplasm due to apc mutation is a com-
mon event in GC. The -catenin proteins accumulate in the 
cytoplasm and some translocate into the nucleus where they 
activate the Tcf/Lef (T cell factor/Lymphoid-enhancer fac-
tor) transcription factor. The -catenin/Tcf complex subse-
quently activates a large number of oncogenes including 
vegf, c-myc, c-jun, fra-1, cyclin D1 and gastrin [84]. Nuclear 
localization and Wnt activation has been reported in ap-
proximately one-third of gastric adenocarcinomas, both in-
testinal and diffuse types [83]. The Wnt pathway is an im-
portant regulator of gastrointestinal stem cell proliferation 
and homeostasis; Wnt pathway activation is a key early 
event in multistep gastric carcinogenesis [83, 85]. Further-
more, a study on the localization and mutation of -catenin 
in GC of different phenotypes demonstrated that nuclear 
accumulation and mutations in exon 3 of -catenin correlate 
with intestinal phenotypic expression in gastric adenocarci-
noma; no mutations were detected in cases with cytoplasmic 
or membranous localization. Early gastric adenocarcinoma 
mainly consists of gastric phenotype malignant cells with 
largely membranous localization of -catenin, whereas ad-
vanced cancers have more malignant cells of the intestinal 
phenotype and nuclear -catenin accumulates during the 
shift from the gastric to the intestinal phenotype [77]. An-
other major mechanism of Wnt signalling activation in GC is 
aberrant methylation and consequent silencing of the se-
creted frizzled-related protein (SFRP) family of genes; this 
may contribute to boosting cellular proliferation and inhibit-
ing apoptosis although the mechanisms for this are unclear 
[86]. SFRP1 inactivation is a common, early event caused 
mainly by hypermethylation in GC; in one study, loss of 
expression was also correlated with tumor stage and lymph 
node status and was suggested to be associated with poor 
prognosis in GC patients [87].  
  The p53 TSG serves as a major cellular barrier against 
cancer development by way of apoptosis induction. P53 gene 
mutations and/or protein accumulation are the most common 
genetic changes in human tumors [88, 89]. The p53 gene is 
frequently inactivated by loss of heterozygosity (LOH), mis-
sense mutations and frameshift deletions, and in addition to 
the loss of wild-type p53, a high percentage of tumor cells 
accumulate mutant P53 protein isoforms [12, 88]. Whilst 
wild-type P53 functions as a tumor-suppressor, tumor-
associated P53 proteins acquire novel functions enabling 
them to regulate gene expression and promote a large spec-
trum of cancer phenotypes [88]. P53 gene mutations are 
more frequent in intestinal than in diffuse type tumors, and 
alterations have been reported to occur at the premalignant 
stages of dysplasia and IM. Thus, p53 mutations have a cru-
cial and early role in gastric carcinogenesis of the intestinal 
type; an immunohistochemical and genetic analysis revealed 
that early tumors with the poorest prognosis (i.e. that deeply 
penetrated the submucosa), showed the highest frequency of 
both p53 gene mutation and of nonmutated protein accumu-
lation. However, p53 mutations and nuclear accumulation 
are late events in diffuse-type GC [89]. P53 belongs to a 
small family of sequence-specific nuclear transcription fac-
tors, to which p63 and p73 also belong [90]. P53 and P73 
share structural and functional similarities; both are potent 
tumor suppressors with different isoforms that accumulate in 
response to DNA damage and have altered functions which 
often oppose those of the wild-type. Isoforms of P73 can 
inhibit both p53 and p73, thus assisting in tumor progression 
in contrast to the wild-type role of tumor suppression. In the 
absence of functional p53, p73 can be responsible for regu-
lating the cell cycle, promoting apoptotic cell death in tumor 
cells and regulating the response of tumor cells to drugs; 
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activity of p73 are distinct from those used by p53. The 
complexity of p73’s activity results in contradiction in its 
role as an important member of the p53 TSG family, thus 
further investigations are needed to fully verify its role in 
cancer [90, 91]. 
  The Puma protein (p53-upregulated modulator of apopto-
sis) belongs to the BH3-only group of proteins along with 
Bcl-2. It is a potent mediator of the p53 apoptotic response 
that dimerizes with other BH3-only proteins resulting in re-
lease of cytochrome C from the mitochondria and induction 
of apoptosis by the activation of caspases 3 and 9 [84]. How-
ever, Puma expression is transactivated by p53 and p73 and 
its expression is increased in gastric carcinomas whilst re-
maining absent in normal gastric mucosa, suggesting it may 
have a potential oncogenic role and could possibly be used 
as a diagnostic marker [92].  
  RunX3 is a TSG which is frequently inactivated by allele 
loss or gene silencing due to promoter hypermethylation in 
GC and many other cancer types [93, 94]. RunX3 methyla-
tion has been detected in many premalignant lesions of gas-
tric carcinomas, including 8.1% of chronic gastritis, 28.1% 
of intestinal metaplasia, 27.3% of gastric adenomas and 64% 
gastric carcinomas [94]. Deletion of the RUNX3 locus in 
mice results in hyperplasia of the gastric epithelium due to 
the stimulation of proliferation and suppression of apoptosis 
that is accompanied by a reduced sensitivity to TGF-1. The 
tumor suppressor activity of RunX3 was demonstrated in 
nude mice when an increase in the level of runX3 expression 
resulted in decreased tumorigenicity. It has therefore been 
elucidated that RunX3 is a tumor suppressor of GC associ-
ated with the Tgf- signalling pathway. Induction of apopto-
sis by Tgf- is well-documented in many cancer cell types; 
however, the role RunX3 plays in Tgf--dependent cell cycle 
arrest and apoptosis is unclear [93]. A more recently pro-
posed molecular mechanism for the anti-tumor activity of 
RunX3 is the inhibition of cancer angiogenesis, growth and 
metastasis. The growth and metastasis of GC depends on 
angiogenesis, the vascular endothelial growth factor, Vegf, 
has been identified as crucial to tumor angiogenesis. RunX3 
was shown to directly suppress vegf gene transcription, 
which results in a significantly impaired angiogenic potential 
in human GC cells. RunX3 and Vegf expression were in-
versely associated and restoration of RunX3 expression in 
cancer cells inhibited tumor growth and metastasis [68].  
  Other TSGs commonly silenced by hypermethylation in 
GC are p14, p15, p16, p57, dap-kinase, hMLH1, e-cadherin 
and rassf1A [95-100]. The ink4a/arf locus encodes the two 
tumor suppressors, p16
INK4A  and p14
ARF, these are closely 
related genes located on chromosome region 9p21. P16
INK4A 
is a cell cycle regulator that inhibits G1-cyclin-dependent 
kinases, Cdk4 and Cdk6, and induces a G1-phase arrest. P15 
also inhibits Cdk4 which mediates cell cycle control, particu-
larly in the Tgf--signalling pathway. Dap-kinase (death-
associated protein kinase) is a pro-apoptotic serine/threonine 
kinase involved in interferon--induced apoptosis. hMLH1 is 
a DNA-mismatch repair gene and E-cadherin is a cell adhe-
sion molecule that binds the  -catenin pathway and has a 
role in the suppression of invasion and metastasis [97]. Hy-
permethylation of these TSGs has been detected in both GC 
and IM and a differential increase in methylation frequencies 
from premalignant to malignant tissues in dap-kinase, p14, 
p15 and p16 suggests accumulation of hypermethylation in 
these loci during progression from metaplasia to cancer [97]. 
Other reports of hypermethylation in GC suggest that it is an 
early event that often occurs in premalignant conditions such 
as IM and accumulates during tumor progression [48, 94, 
101-103].  
  The cyclin-dependent kinase inhibitors p21 and p27 share 
42% amino acid homology and whilst both had reduced ex-
pression in GC, the expression levels of each differed in dif-
ferent types of disease, with p27 loss associated with the 
sporadic form (Type III), and p21 loss associated with hy-
pergastrinaemic cases (Type I or II) [104]. P21 functions as a 
cell growth cycle inhibitor and inhibits activities of the on-
cogenic cell cycle regulators, cyclins D1 and E [63]. A novel 
functional role of the tumor suppressor p21 has been pro-
posed as an accelerant of Tgf-1-mediated apoptosis in GC 
cells [105].  
5.3. MicroRNAs 
  MicroRNAs are an important class of genes which func-
tion alongside TSGs and oncogenes and are involved in gene 
silencing and dysregulation during tumorigenesis. They are 
members of the small RNA family which include small in-
terfering RNAs (siRNAS). Both micro RNAs (miRNAs) and 
small interfering RNAs (siRNAs) are evolutionary con-
served, non-coding, small RNAs (21-25 nucleotides) in-
volved in post-transcriptional gene regulation. About 200-
300 miRNAs have currently been identified in humans and 
of these, about 50% are involved in cancer with either TSG 
or oncogenic functions [49, 50, 57-60, 106].  
  Some tumor suppressor miRNAs may be relevant in GC 
due to their interference with genes commonly deregulated 
in GC. The miRNAs miR-15a and miR-16a induce apoptosis 
by targeting Bcl2 [49, 60]; and the let-7 family of miRNAs 
have tumor suppressor activity by way of negative regulation 
of ras [49, 50, 57-59]. Let-7 and ras are reciprocally ex-
pressed in lung tumor tissue versus normal tissue where let-7 
homologs were down-regulated and ras up-regulated; let-7 
has been suggested as a potential therapeutic agent to treat 
lung cancer [58, 59].  
  The first of the oncogenic miRNAs that was shown to 
have tumorigenic activity was Bic/miR-155. This gene func-
tions as an oncogene in cooperation with Myc and has been 
consistently observed in many tumor types including breast, 
lung, colon and thyroid cancers [49, 50], and may yet be 
relevant for GC. The microRNA miR-21 promotes tumori-
genesis by inhibiting apoptosis and its overexpression has 
been reported in many tumor types including breast, colon, 
lung, pancreas, stomach and prostate [49, 50]. The miR-17 
cluster refers to a miRNA polycistron located at chromo-
some 13q31, consists of a cluster of 6 human miRNAs (miR-
17-5p, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92), 
that has been implicated as an oncogene. It has been shown 
to be under direct control of c-myc, and the two function in 
concert to promote cell cycle progression and inhibit apopto-
sis [49, 50, 57-62]. Two miRNAs, miR-372 and miR-373, 
render cells insensitive to the effects of a normally function-
ing p53 allele by inhibiting expression of lats2 (large tumor 
suppressor homolog 2), this in turn relieves Cdk2 from 388    Current Genomics, 2007, Vol. 8, No. 6  Holmes et al. 
Table 1.  Oncogenes and Other Genes Aberrantly Overexpressed in IM and Intestinal-Type GC and their Functional Role 
Gene Name 
Expression During  
Intestinal Differentiation 
Expression  
in IM 
Expression  
in GC 
Functional Role in IM/GC 
Cdx1  + +  + + +  +  Regulator of intestinal cell lineage differentiation 
Cdx2  + +  + + +  +  Regulator of intestinal cell lineage differentiation 
Muc2  + +  + + +  +  Associated with intestinal cell lineage differentiation 
Cldn4 (claudin-4)  +  + + +  + + +  Associated with intestinal cell lineage differentiation 
Cldn7 (claudin-7)  +  +  + + +  Associated with intestinal cell lineage differentiation 
Mkk-4  +  + + +  + + +  TSG associated with intestinal cell lineage differentiation 
Stratifin  +  + + +  + + +  Associated with intestinal cell lineage differentiation 
Villin-1  +  + + +  + + +  Associated with intestinal cell lineage differentiation 
Hif-1  + +  + + +  +  Associated with intestinal cell lineage differentiation 
Fabpi  + +  + + +  +  Associated with intestinal cell lineage differentiation 
Tff1 (trefoil factor 1)  + +  + + +  +  Associated with intestinal cell lineage differentiation 
Tff3 (trefoil factor 3)  + +  + + +  +  Associated with intestinal cell lineage differentiation 
Gcc  + +  + + +  +  Associated with intestinal cell lineage differentiation 
Cdh17 (li-cadherin)  + +  + + +  + +  Cdx-2 regulated intestine-specific gene, associated with invasiveness and LNM 
Defa5    + + +  + +  Cdx2-regulated intestine-specific gene 
Furin  + +  + + +  + +  Essential for morphological differentiation of intestinal cells 
Oct-1  + +  + + +  +  Transcription factor, binds cdx2 promoter 
Myo1A  + +  + + +  +  Intestinal-transformation specific indicator gene 
Mtp  + +  + + +  +  Intestinal-transformation specific indicator gene 
Fat  + +  + + +  +  Intestinal-transformation specific indicator gene 
P53 (mutants)  +  + +  + + +  Regulate gene expression and promoted carcinogenesis 
P73 (mutants)  +  + +  + + +  Inhibit WT p53 and p73 and promote tumor progression 
K-ras (mutation)    + +  + + +  Oncogene, frequently mutated in intestinal-type GC 
C-myc    + +  + + +  Cell cycle regulator, associated with tumor aggressiveness 
C-erbB2      + + +  Overexpression involved in gene amplification, poor prognosis and metastases 
Cyclin D1      + + +  Cell cycle regulator 
Cyclin E      + + +  Cell cycle regulator, associated with lymph node metastases 
Top2A      + + +  Involved in cell cycle and proliferation 
Cdc2      + + +  Promotes cell cycle and proliferation 
Mmp (1-3, 7, 9-14)      + + +  Promote angiogenesis and proliferation in GC 
CD44    + +  + + +  Transmembrane glycoprotein; involved in cell-cell matrix interaction 
-catenin    +  + + +  Accumulates due to APC mutation, activates many oncogenes 
Vegf      + + +  Growth factor, mediator of tumor angiogenesis 
Pot1      + + +  Associated with telomere dysfunction and LOH 
hTERT    + +  + + +  Associated with telomere dysfunction and LOH 
miR-17 cluster      + + +  Drives cell cycle progression and inhibits apoptosis; acts in concert with c-myc 
miR-372      + + +  Render cells insensitive to wild type p53 
miR-373      + + +  Render cells insensitive to wild type p53 
Key to Table 1:  
+/+ +/+ + +  refers to gradual increase in expression/mutation 
+ Expressed  
++ Upregulated 
+++ Overexpressed Genetic Mechanisms and Aberrant Gene Expression  Current Genomics, 2007, Vol. 8, No. 6    389 
Table 2.  TSGs and Other Genes Aberrantly Expressed and Silenced in IM and Intestinal-Type GC and their Functional Role 
Gene Name 
Expression During  
Intestinal Differentiation 
Expression 
in IM 
Expression 
in GC 
Functional Role in IM/GC 
Muc1  -  - -  - - -  Associated with gastric-type cell lineage 
Muc5AC  -  - -  - - -  Associated with gastric-type cell lineage 
Muc6  -  - -  - - -  Associated with gastric-type cell lineage 
Sox2  -  - -  - - -  Associated with gastric-type cell lineage 
P53 (wild-type)  -  - -  - - -  Induces apoptosis, inactivated by LOH 
P73 (wild type)  -  - -  - - -  TSG, induces apoptosis, belongs to p53 family 
RunX3  -  - -  - - -  TSG silenced by hypermethylation; initiates Tgf--induced apoptosis, suppresses Vegf 
P21 (WAF1/CIP1)      - - -  Cell growth cycle inhibitor, inhibits cyclins D1 and E 
P27 (KIP1)      - - -  Cell growth cycle inhibitor, inhibits cyclins D1 and E 
Apc (mutation)    -  - - -  TSG: degrades -catenin 
Tgf--signalling pathway      - - -  TSG: Induces apoptosis 
P14 (ARF)    - -  - - -  TSG: regulates cell cycle, silenced by hypermethylation 
P15 (INK4B)    - -  - - -  TSG: regulates cell cycle, silenced by hypermethylation 
P16 (INK4A)    - -  - - -  Cell cycle regulator, induces G1-phase arrest, silenced by hypermethylation 
P57 (KIP2)    - -  - - -  Inhibits cyclin-dependent kinases, silenced by hypermethylation 
Dap-kinase    - -  - - -  Death-associated protein kinase involved in apoptosis, silenced by hypermethylation 
hMLH1    -  - - -  DNA mismatch repair gene inactivated by hypermethylation; causes MSI 
Key to Table 2: 
-/- -/- - - refers to gradual decrease in expression/mutation 
- Minimal/reduced expression 
- - Downregulated 
- - - Silenced 
 
repression, allows continuing cellular proliferation and over-
comes cellular senescence [49, 50]. 
  The P13K/Akt signalling pathway results in aggressive 
proliferation and is activated in most tumors, including gas-
tric adenocarcinoma [107-109]. The tumor suppressor gene, 
pten (phosphatase and tensin homolog on chromosome ten), 
inhibits P13K function. Loss of pten expression is associated 
with P13/Akt signalling activation in many tumors. MiR-19a 
binds pten in vitro, and overexpression of miR-19 in lym-
phomas correlates with reduced expression of the Pten pro-
tein, thus overexpression of miR-19 in tumors could repre-
sent an alternative mechanism of activation of the P13K/Akt 
signalling pathway [58].  
  Loss or gain of function of specific miRNAs appears to 
be a key event in the genesis of diverse cancers including 
GC, such that miRNAs are now known to regulate pathways 
controlled by classic tumor suppressors and oncogenes in-
cluding p53, myc and ras [49]; these genes are all involved 
in GC. [58, 59]. Thus, a tumor suppressor or oncogenic 
miRNA may represent an ideal target for diagnosis, progno-
sis and therapeutic intervention of many cancers.  
  Tumorigenesis involves the accumulation of multiple 
mutations and genetic changes and most human tumor cells 
contain multiple chromosomal abnormalities [110, 111]. 
Two major classes of genetic instability have been character-
ized: microsatellite instability and chromosomal instability 
[111].  
5.4. Microsatellite Instability (MSI) 
  Microsatellite instability (MSI) results in defective DNA 
repair processes; it is a hallmark of the DNA mismatch re-
pair deficiency that is one of the main pathways of gastric 
carcinogenesis. Microsatellites are short DNA sequence re-
peats found throughout the genome and nearly always pre-
sent in GC cases associated with germline mutations of the 
mismatch repair (MMR) genes: hMsH2, hMLH1, hPMS1, 
hPMS2 and MSH6/GTBP [12]. In most gastric adenocarci-
nomas, MSI originates from inactivation of the hMLH1 gene 
promoter by hypermethylation [98, 112]. MSI of the D1S191 
locus is found in 26% of IM and 46% of intestinal-type can-
cer [12]. Furthermore, a study on early gastric neoplasms 
demonstrated that hypermethylation-associated inactivation 
of the hMLH1 gene can occur in early gastric carcinogenesis 
and the MSI- and hypermethylation-associated inactivation 
of hMLH1 are more prevalent in early GC than in gastric 
adenoma [113].  
5.5. Chromosomal Instability 
  Chromosomal instability involves losses of heterozygos-
ity (LOH) and a likely cause of this is telomere dysfunction 
[111]. Telomeres are required for the stable transmission of 
linear chromosomes and in normal human somatic cells, and 
they shorten gradually with age. The telomere specific pro-
tein, Trf1, regulates telomere length, and Trf2 maintains te-
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cer cells, however, do not shorten, this is maintained by te-
lomerase by way of extending 3’ telomeric overhangs or 
recombination [115]. In GC, reduced levels of expression of 
a single-stranded telomeric DNA-binding protein, protection 
of telomeres (Pot1) has been associated with telomere dys-
function, and changes in Pot1 expression levels were poten-
tially associated with stomach carcinogenesis and GC pro-
gression [115]. Most intestinal-type GCs have elevated te-
lomerase activity and expression of hTERT (human telom-
erase reverse transcriptase; the enzyme that catalyzes te-
lomere DNA synthesis) resulting in shortened telomere 
length; over 50% of IM expresses low levels of telomerase 
activity, equivalent to 10% that in GC [12]. 
5.6. DNA Methylation 
  One of the most frequent mechanisms of gene inactiva-
tion in GC is epigenetic silencing by DNA methylation. 
DNA methylation is a chemical modification that alters the 
phenotype of a gene without altering its DNA sequence. 
Gastric carcinoma is one of the tumors that has a high fre-
quency of CpG island hypermethylation; CpG islands are 
short CpG-rich regions present within the promoter region of 
approximately 40-50% of human genes [101-103, 116]. The 
concordant methylation of multiple genes is termed as the 
CpG island methylation phenotype (CIMP); this is the phe-
notype most often associated with gastric carcinoma and is 
characterized by tumors methylated at multiple loci “methy-
lated in tumors” known as the MINT loci (MINT1, MINT2, 
MINT12, MINT25 and MINT 31) [48, 103]. Hypermethy-
lated CpG islands in gene promoters causes subsequent loss 
of transcription of the genes, referred to as gene silencing 
[103, 117, 118]. DNA methyltransferase 1 (Dnmt1) is the 
main enzyme involved in this [47, 118]. Tumor-suppressor 
and tumor-related genes known to be silenced in GC due to 
promoter hypermethylation include p14, p15, p16, p53, p57, 
hMLH1, cdh1 (e-cadherin), apc, chfr, cox2, dap-kinase, 
gstp1, hpp1, mgmt, rassf1A, runX3, timp-3 and thbs1 [10, 
47, 48, 94, 98, 100-103, 116]. There are multiple reports of 
the association between MSI and hypermethylation; inactiva-
tion of the mismatch repair gene hMLH1 is known to cause 
MSI [98, 113, 117, 119]. Demethylation of CpG sites within 
genes, also known as hypomethylation, is also involved in 
GC progression via  a process of activation of oncogenes 
including r-ras, elk1, frat2, fgfR2, rhoB and rho6 [80]. A 
study using siRNA in R-ras-expressing GC cell lines demon-
strated that blocking the r-ras signalling pathway is a poten-
tially successful candidate for GC therapy [80]. 
  Hypermethylation in GC is reported to be an early event 
that accumulates during tumor progression [48, 94, 101-
103]. Hypermethylation and consequent silencing of p16, 
p57 and runX3 have been shown to occur at the early stages 
of gastric carcinoma [93, 94, 100]. It has been reported that 
methylation of p16 may play a role in the malignant trans-
formation of gastric precursor lesions; p16 methylation was 
present in 7% IM, in 18% adenomas unassociated with car-
cinoma, in 29% of adenomas/dysplasias associated with ade-
nocarcinoma and, finally, in 44% adenocarcinomas [103]. 
Other genes predominantly methylated at the early carcino-
genic stages of gastric carcinogenesis, including IM and 
dysplasia, are: dap-kinase, e-cadherin, p14, thbs1 and timp-3 
[102]. 
  Aberrant DNA methylation is more frequently present in 
GC than mutations, and as such presents a useful tool to 
identify novel TSGs [120]. Helicobacter pylori has been 
shown to induce aberrant methylation in gastric mucosae 
[121], and promoter hypermethylation is frequently detected 
in premalignant gastric IM, regardless of the presence or 
absence of tumor [97]. Aberrant methylation patterns repre-
sent useful biomarkers for cancer detection, the assessment 
of prognosis, as therapeutic targets and for the prediction of 
response to anti-tumor treatment; furthermore, they may be 
useful to detect past exposure to carcinogens such as H. py-
lori and assess future risk of cancer development [100, 120, 
121].  
6. GENE EXPRESSION STUDIES OF IM AND GC 
  At present, there are limited reports of human gene ex-
pression in IM, particularly using genome-wide and other 
molecular transcriptional-based studies, such as microarray 
technology and RT-PCR. As described in section 2, many 
expression studies have defined the morphological character-
istics and identified the expression of certain genes his-
tologically which are related to various types and stages of 
IM. Reports of expression profiles of other precancerous 
conditions have also been undertaken including studies of 
gene expression profiles associated with gastric hyperplastic 
polyps [122] and gastric adenoma [123]. Gene expression 
studies of gastric IM using cDNA microarrays include a 
study on inflammation, metaplasia and tumor development 
in mice [124], a study on IM versus GC tissues obtained 
from GC patients during resection [125] and studies of gene 
expression profiling of malignant and non-malignant lesions 
of the esophagus and stomach using fresh patient tissues 
[126, 127]. There are, however, numerous studies that pre-
sent results of microarray gene expression profiling of GC, 
some comparing GC to normal tissues, some distinguishing 
the gene expression profile of the different types of cancer 
i.e. intestinal versus diffuse and a small number which com-
pared GC to its precursor lesions. An overview of the most 
relevant microarray expression studies involving IM com-
parisons and clustering of different cancer types is included 
here. 
6.1. Gene Expression Profiling of GC versus IM and 
other Precursor Lesions 
  The first report of microarray gene expression profiling 
of GC and its precursor lesions was a study of 91 Australian 
and 33 Chinese patients to distinguish the gene expression 
patterns related to clinical, pathological and ethnic parame-
ters [125]. This study and many others have used microarray 
expression profiling to classify tissue samples into malig-
nant, pre-malignant and non-malignant groups as well as 
distinguishing the two types of cancer (intestinal and diffuse) 
by expression profile. Data such as this may prove to be of 
significant use in diagnosis, prognosis and choice of treat-
ment for future patients. Tumor and normal samples were 
collected from patients with GC requiring resection consist-
ing of 65 tumor samples, 22 IM samples, 27 chronic gastritis 
samples and 9 normal tissue samples. Unsupervised cluster-
ing of the data distinguished malignant and non-malignant 
groups, and also different histological groups including 
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diffuse and mixed. A clear segregation of the GC samples 
was not evident between Australian and Chinese patients 
indicating a lack of ethnic differentiation in the molecular 
profile of GC. The chronic gastritis group was defined by a 
mitochondrial gene expression signature, in particular, nu-
clear genes encoding mitochondrial proteins including cyto-
chrome c oxidase (Cox) and NADH dehydrogenase (Nduf). 
This may be linked to H. pylori infection, which is invariably 
present in this group. The expression profile of IM reflected 
expression of genes characteristic of the intestine represent-
ing a transition toward a transformed phenotype; these in-
cluded cdx1, myo1A, the microsomal triglyceride transfer 
protein MTP, cholecystokinin, villin-1, fat and trefoil fac-
tor1, tff1. Many markers of mature intestinal cell function 
showed decreased expression or loss of expression in intesti-
nal-type GC, possibly representing less differentiation in 
tumor tissues than in metaplastic tissues, this was evident in 
Tff1 which had reduced expression in over half of the intes-
tinal and diffuse GC samples [125].  
  Other premalignant tissue types that have been studied 
using expression microarrays include Barrett’s Esophagus 
(BE), gastric polyps and adenoma. A microarray expression 
profiling study of resected human IM samples was used to 
investigate the classification of Barrett’s disease and associ-
ated conditions including IM, GC and adenocarcinoma of the 
esophagus and gastroesophageal junction (GEJ) [127]. Bar-
rett’s esophagus describes the condition of IM in the esopha-
gus which has a strong association with gastric IM; both are 
considered as lesions with higher risk of malignant transfor-
mation to adenocarcinoma in the esophagus and stomach, 
respectively, and both are associated with inflammatory 
stimuli. Specific functional modules were identified that had 
significant levels of altered gene expression: the glycolipid 
metabolism module and the cytokine-cytokine receptor in-
teraction module. Genes within the cytokine-cytokine recep-
tor module were expressed at high levels in samples of IM 
and Barrett’s oesophagus. A stronger correlation was ob-
served between adenocarcinomas of the esophagus and IM 
of the stomach than with Barrett’s mucosa and all but one 
carcinoma of the GEJ clustered together with adenocarcino-
mas of the stomach. This led the authors to speculate that 
adenocarcinomas of the esophagus could originate at the 
cardia invading the esophagus from below. In summary, the 
study was able to select a small set of genes that define new 
hypotheses for the malignant transformation of IM to adeno-
carcinomas [127]. A previous study differentiated Barrett’s 
Esophagus (BE) compared to cardia intestinal metaplasia 
(CIM) using their expression profiles and suggested this 
might provide a new direction for diagnosis, therapy and 
prevention of BE [126]. Many other studies have been pub-
lished of the gene expression profile and molecular events 
involved in Barrett’s Esophagus, [128-132] but as this is 
considered to be a precursor lesion for a separate type of 
adenocarcinoma than gastric IM, it will not be discussed in 
any further detail for the purpose of this review. 
  Microarray gene expression profiling was employed to 
study the chromosomal instability and consequent differen-
tial expression of 11 gastric polyps with intraepithelial neo-
plasia (dysplasia); three hyperplastic polyps and eight ade-
noma. Although only a minority of gastric cancers are likely 
to actually arise from adenomas, they provide a defined op-
portunity to survey chromosomal changes during the patho-
genesis of GC. Hyperplastic polyps are thought to be reac-
tive in nature rather than neoplastic, yet are occasionally 
implicated in the onset of GC. Gene expression profiles re-
vealed that both types of polyp showed many chromosomal 
aberrations, several consistent with gastric malignant lesions, 
the most frequent was loss of 9p21.3. The authors suggest a 
link between the distinct aberrations for each type of polyp 
with two morphologically and genetically distinct pathways 
to GC; the hyperplastic polyp pathway and the (intestinal 
type) adenoma pathway [122]. A subsequent study to com-
pare expression profiles of gastric adenoma with gastric ade-
nocarcinoma identified three distinct gene clusters consistent 
with the grade of adenoma. Group 1 contained mainly small, 
low-grade adenomas characterized by gene expression con-
sistent with normal stomach, group 2 contained mainly large 
low and high grade adenomas characterized by the over- 
expression of intestine-specific genes including the cdx2-
regulated cdh17 and defa5. The upregulation of the intesti-
nal-type cell lineage is implicated in the pathogenesis of in-
testinal-type adenocarcinoma. Group 3 contained mainly 
gastric adenocarcinoma characterized by overexpression of 
arg2, a gene that has been reported to be overexpressed in 
many cancers including gastric adenocarcinoma. The genes 
reported to be expressed in this study are different to the 
spectra that are usually reported in DNA microarray studies, 
it is suggested this may be due to the fact that many studies 
report on the gene expression of advanced stage carcinoma 
which may exhibit a different gene expression profile to the 
tissue studies here [123].  
6.2. Expression Profiles of Diffuse-type Gastric Cancer 
(DGC) versus Intestinal-Type Gastric Cancer (IGC) 
  The Boussioutas study previously discussed [125] high-
lighted differential expression of genes involved in diffuse-
type gastric cancer (DGC) versus intestinal-type gastric can-
cer (IGC). The gene expression signature of DGC reflected 
active extracellular matrix production and complex signal-
ling and remodelling by cell growth regulators. DGC is char-
acterized by a marked stromal reaction and genes encoding 
components of the extracellular matrix were overexpressed, 
including collagens, matrix metalloproteinases, osteoglycin 
and cadherin 11. Smooth muscle and cell adhesion molecule 
genes were upregulated as well as a number of genes encod-
ing extracellular proteins that are linked to the regulation of 
cell proliferation, including secreted frizzled-related protein 
4, Nmb, Dab2, SparC, Wnt5a, Dkk3 and Fdz1; however, 
many of these were also upregulated in IGC. Significant at-
tenuation of Cdh1 expression was found in DGC compared 
to other tissues, this is a recognized feature of DGC and 
germline mutations of Cdh1 are associated with familial 
DGC [125, 133-135]. In contrast, the IGC expression profile 
was characterized by markers of cell division and prolifera-
tion, many of which were not elevated in DGC samples, in-
cluding genes required for G2-M transition, DNA replica-
tion, spindle assembly and chromosome segregation. Many 
genes with differential expression have been associated with 
GC and other cancers in other reports, such as topoisomerase 
(top2A) and cdc25B [70, 74]. Classification of different 
types of cancer was performed in a subsequent study which 
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ent types of GC but few genes are named specifically [8]. Of 
note, diminished expression of the vhl gene in intestinal type 
adenocarcinomas and overexpression of matrix metalloprote-
inase (mmp2) were identified in the diffuse-type cancers. 
However, following hybridization to tissue arrays, Mmp2 
was found to be overexpressed in both intestinal and diffuse-
type cancers [8]. These data are supported by further studies 
which used clustering of gene expression profiles to distin-
guish DGC from IGC [136, 137]. Consistent with other stud-
ies, genes upregulated in diffuse versus intestinal type cancer 
included genes associated with cell adhesion or migration 
and the extracellular matrix, including sparC, tubB2, itgB1, 
arhgd1A, col1A1 and col1A2. The genes which were 
upregulated in intestinal type versus diffuse type GC in-
cluded growth-factor receptor genes (grb10, isr2 and 
eps15R) and genes related to cellular proliferation and mito-
chondrial function (egfr, egr1, pcna, cdk2, psort, timm10 and 
bcat2). The different nature and mechanisms of the two types 
of cancer are represented by this data which, after further 
analysis, revealed 46 genes that clearly separated the two 
classes of tumor [137]. Hippo et al. [74] reported genes ex-
clusively overexpressed in intestinal-type cancer following 
microarray expression analysis. Overexpression was reported 
of the intestinal enzyme genes reflective of intestinal differ-
entiation (galc, guyc2 and gpx2), the intestinal differentia-
tion marker li-cadherin (cdh17) of the cadherin family genes 
which have crucial roles in cell-cell adhesion, and c-erbB2 
was exclusively expressed in intestinal-type cancer, thus 
reflecting gene amplification [74].  
6.3. Expression Profiles of Malignant versus Non-
Malignant Tissues 
  Molecular classifiers for GC and non-malignant diseases 
of the gastric mucosa, including IM, were identified using a 
cDNA microarray approach [8]. The study comprised of 
microarray expression profiling of 28 GC tissues (including 
18 intestinal-type and 10 diffuse-type) and 71 non-tumor 
gastric tissue samples (including 28 normal, 21 gastritis and 
22 IM) obtained during surgery or by endoscopy. Molecular 
classifiers were identified based on trios of genes defined by 
Fisher’s linear discriminant analysis; tissue samples were 
discriminated at the distinctive stages during the carcino-
genesis cascade, the two types of adenocarcinoma, gastric 
and diffuse, were also discriminated. More genes were differ-
entially expressed between tumor and normal samples than 
between IM and normal samples. No genes were found that 
could distinguish normal from gastritis tissue samples. Genes 
that had their expression progressively altered during the 
cascade of intestinal-type carcinogenesis (i.e. Correa’s cas-
cade including metaplasia stage) were as follows: genes with 
increased expression; col1A1, fn1, ctsb, col1A2, hs.177781, 
daf and vim; genes with decreased expression were prpf8, 
hs.327751, vhl, lck, bad, vegfB and polr2H [8].  
  A microarray study of 22 GCs and 8 noncancerous gas-
tric tissues identified 162 genes upregulated in cancer versus 
non-cancerous tissue which included genes known to be in-
volved in GC. Immunohistochemical detection of high levels 
of -catenin and e-cadherin supports other studies suggesting 
that mutation and nuclear accumulation of -catenin is pre-
dominant in intestinal-type cancer and loss of e-cadherin is 
predominant in diffuse-type cancer [74]. Yu et al. [138] per-
formed a microarray study of differential gene expression in 
GC, pericancerous epithelium and normal gastric mucosa. 
The study identified 35 genes upregulated in pericancerous 
epithelium and GC versus normal tissues, including cam-5 
(CEA: cell-associated adhesion molecule 5) and cam-6. In 
pericancerous epithelium versus GC tissue, 6 genes were 
upregulated and 3 genes were downregulated [138]. CEA is 
a broad spectrum tumor marker which is suggested here to 
be a useful marker for GC and is reported elsewhere to be 
upregulated in GC [139]. Topoisomerase2 (top2) was also 
overexpressed versus normal tissue, this gene is involved in 
the increase in cell proliferation from S phase to G2/M phase 
of the cell cycle that has been reportedly overexpressed in 
previous GC studies [53, 70]. Significant upregulation of e-
cadherin and integrin-4 was demonstrated as consistent 
with previous reports [70, 74, 139], cell skeleton and exter-
nal matrix protein genes were also upregulated consistent 
with previous studies [70, 74, 137]. These genes play an im-
portant role in tumor invasion [138].  
6.4. Expression Profiling of Mouse Models of IM and GC 
  Gene expression studies have been used to assess the 
efficacy of mouse models of human gastric inflammation, 
metaplasia and tumor development. The gastrin-deficient 
mouse has been demonstrated to represent a new, useful 
model for how Helicobacter-negative achlorhydria predis-
poses to GC. Specific changes in gastric gene expression 
included activation of immune defense genes, interferon-
regulated response genes and IM of the gastric mucosa was 
characterized by expression of intestinal-type genes includ-
ing cdx1, cdx2, muc2, villin-1 and claudin 7 [124]. A profile 
of gene expression changes in Helicobacter-induced GC was 
demonstrated by infecting hypergastrinaemic mice with H. 
felis [76]. Gene expression alterations were characteristic of 
those seen in human GC samples including two growth fac-
tors that are known to be highly expressed in human GCs, 
reg1 and amphiregulin [140, 141]; members of the matrix 
metalloproteinase family, mmp-10 and mmp-13; and clau- 
din-7 [19, 21, 24]. Genes consistent with H. pylori infection 
and hypergastrinaemia exhibited altered expression, and cy-
tokines involved in the inflammatory response had altered 
expression, including upregulation of expression of the Th1 
cytokines interferon-, il-1 and tnf-. Deregulation of these 
genes in the mouse model mimics the pathway towards GC 
in humans following H. pylori infection [76]. 
6.5. Microarray Expression Profiling Summary 
  Microarray expression profiling has been used exten-
sively in studies of GC, with results between investigators 
showing consistency in the majority of cases. Not all reports 
agree on all the same genes but there is greater consistency 
in finding general groups and families of genes with aberrant 
expression in certain tissue types, for example, the up-
regulation of genes involved in proliferation in intestinal-
type GC. It could be argued that most cancer types would 
yield a higher expression of proliferation marker genes; 
however, many studies have been successful in using mi-
croarray technology to distinguish the different types of can-
cer. A consensus has been reached between numerous inves-
tigators regarding this, and a general expression profile of 
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is largely agreed. For this reason, many microarray studies 
have suggested their use for predicting the diagnosis [142], 
prognosis and metastatic potential of GC [137, 143], and 
also to possibly determine survival and choice of appropriate 
therapy [75]. Furthermore, a study that used microarray 
expression profiling to investigate gene expression in gastric 
adenomas proposed that their results may be capable of de-
fining subgroups of adenoma that are unresolved by conven-
tional histopathology which may have a prognostic value 
should a follow-up study be undertaken [123]. 
  Whilst microarray expression profiling of GC has been 
demonstrated to have a very low level of variability within 
the same tumor sample [144], this variability may be more 
pronounced when using other techniques and methodologies. 
A group in Japan used SAGE analysis with confirmation by 
RT-PCR to examine the expression profiles of GC and 
lymph node metastatic tissue. They identified changes in 
some genes previously reported in GC, as well as some 
novel gene expression alterations. They suggest that gene 
expression patterns of GC in Japan may be different from 
those in USA and Europe [139]. This is an interesting view-
point that conflicts with previous research that investigated a 
geographic variation in GC expression profiles and found no 
difference [125]. This is the only report that suggests differ-
ences in data may reflect geographical differences [139]. 
Differences in methodology and techniques between labora-
tories is a likely factor contributing to these differences; an 
alternative explanation may be due to the differences that 
exist between Japanese and Western gastrointestinal pa-
thologists in classification of dysplasia and cancer [145]. In 
summary, microarrays are proving to be very useful for clas-
sifying different tumor and tissue types, they may yet be 
useful for prognosis, diagnosis and treatment choices, but 
investigators must proceed with caution due to the problems 
in interpretation and consistency of microarray data as high-
lighted above. 
7. SUMMARY AND FUTURE DIRECTIONS 
  This review has attempted to highlight the current situa-
tion of the known molecular events involved in the initial 
development of intestinal metaplasia and its subsequent pro-
gression into gastric cancer. Whole-genome microarray ex-
pression profiling has proven to be a very useful methodol-
ogy for defining subgroups within GC and defining malig-
nant tissue from non-malignant tissue; however, this tech-
nique has not as yet managed to expand on the intestinal-cell 
type markers of IM that have been very successfully defined 
by immunohistochemical analyses. Most markers appear to 
differentiate either intestinal-type or gastric-type cells and 
the expression of these progressively increases or decreases 
accordingly throughout the development of IM and GC, in-
cluding such genes as the intestinal markers cdx1, cdx2 and 
cdh17, and the gastric marker gene, sox2. Thus, genes which 
have high levels of expression in IM and GC that could be 
potential markers of IM malignancy, have not been reported 
from immunohistochemical or whole-genome microarray 
analysis. The most useful technique to date, which has been 
able to identify genes with the same aberrant expression pat-
terns in IM and GC, is methylation profiling. Many hyper-
methylated genes are known to be highly expressed in IM 
and GC, these include p53, p16 and runX3. DNA methyla-
tion is thus a key molecular mechanism in the development 
of GC and its presence links precursor lesions such as IM 
with the development of tumor tissues. The presence of 
miRNAs is also a new, exciting field which could yield 
enormous insights into the molecular mechanisms of aber-
rantly expressed genes in IM and GC. Research into this 
field and its role in cancer is still in the early stages, yet al-
ready, genes associated with IM and GC have been impli-
cated as having microRNA interference in their regulation, 
including p53 and c-myc. 
  Future applications of new and improved technologies 
may yet be able to provide useful genetic markers which 
could allow for early detection of GC, by enabling diagnosis 
at the precursor stage of IM. Indeed, one of the immunohis-
tochemical studies using suggested potential future endo-
scopic application of the IM and dysplasia detection markers 
Claudin-4, Mkk4 and Stratifin, whereby labelled antibodies 
could be used to identify precursor lesions during the endo-
scopic procedure as a rapid screening method [3]. Further 
research is needed into potential molecular markers of GC at 
the precursor lesion stage and the application of marker de-
tection techniques in a clinical environment. There is consid-
erable potential to exploit miRNAs and gene hyper- and 
hypo-methylation for diagnosis and therapeutic intervention 
of cancer. A potential therapeutic intervention that has been 
proposed to date is by targeting miRNA regulation with an-
tisense oligonucleotides, referred to as anti-miRNA nucleo-
tides (AMOs), that are complementary to mature oncogenic 
miRNAs and might effectively inactivate miRNAs in tumors 
and slow tumor growth [58, 59]. Future progress in the 
above research fields, incorporating both studies at the 
whole-genome level and studies of specific genes and their 
regulatory pathways, are hoped to further define and clarify 
the precise pathways of molecular and genetic events in-
volved in the development of IM and subsequent progression 
into GC. The translation of these findings into a clinical set-
ting for diagnosis and treatment of GC will maximize the 
future potential of this research. 
ABBREVIATIONS 
IM =  Intestinal  Metaplasia 
GC =  Gastric  Cancer 
IL-1 =  Interleukin-1 
TNF-   =  Tumor Necrosis Factor- 
TSG  =  Tumor Suppressor Gene 
DGC  =  Diffuse-Type Gastric Cancer 
IGC =  Intestinal-Type  gastric  Cancer 
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